INSIGHTS ON UPSTREAM MANUFACTURING
-
![Innovating Upstream AAV Manufacturing For The Next Wave Of Gene Therapies Bucket]( "Innovating Upstream Manufacturing For The Next Wave Of Gene Therapies")
Innovating Upstream Manufacturing For The Next Wave Of Gene TherapiesExplore a streamlined approach to transient AAV production, including yield improvements across serotypes, key transfection parameters, and practical guidance for scaling processes.
-
![GettyImages-2149039471 scientist lab microscope]( "Mesenchymal Stromal Cells: The Progress And Manufacturing Challenges")
Mesenchymal Stromal Cells: The Progress And Manufacturing ChallengesUnderstand the manufacturing challenges where rapid cell expansion often conflicts with therapeutic secretion profiles, requiring sophisticated quality control and donor selection strategies.
-
![clinical-drug-development-GettyImages-1354172647]( "Getting Your Proof Of Clonality Right For Regulators")
Getting Your Proof Of Clonality Right For RegulatorsRegulators require clear, verifiable proof that production cell lines originate from a single progenitor cell, supported by strong imaging, documentation, and data integrity to ensure product consistency and safety.
-
![bioassays-cell-GettyImages-1493793527]( "What Makes A Cell Bank 'GMP-Ready'?")
What Makes A Cell Bank 'GMP-Ready'?A GMP‑ready cell bank requires controlled stability, sterility, genetic integrity, and complete documentation to ensure consistent, safe biologic production and meet regulatory expectations.
-
CHO Cell Line Performance With 2G UNic® Technology2/27/2026
Optimized vector designs significantly enhance CHO cell protein expression, yielding higher titers, better stability, and strong performance across diverse host lines and scale‑up stages.
-
How Early Data Drives Better Cell Line Performance2/27/2026
Structured early data strengthens clonality assurance, stability, and tech transfer, supporting consistent performance, lower variability, and smoother progression to manufacturing.
-
A Journey To Produce MSC-Derived Cell Therapies From Isolation To Large-Scale2/26/2026
Drive successful MSC therapy development by optimizing isolation methods, surface chemistry, and closed-system expansion technologies to ensure cellular stability and commercial scalability.
-
Scaling MSC Therapies: Overcoming Cell Therapy Manufacturing Risks And Barriers2/26/2026
Achieve scalable MSC manufacturing by implementing closed systems and modular scale-out strategies that minimize contamination risks and ensure consistent cellular stability and efficacy.
UPSTREAM MANUFACTURING SOLUTIONS
-
![Nucleus - pod loading bucket]( "Krakatoa® K500 On-Demand Media And Buffer Manufacturing System")
Enable co-location of cell culture media and buffer manufacturing and bioproduction with Krakatoa K500, the first bioreactor-scale pod-based manufacturing system. Produce up to 500 liters of sterile solutions on-demand in less than 3 hours.
-
![Nucleus - Krakatoa K500]( "Krakatoa® K500: The Future Of Media And Buffer Manufacturing")
Find out how automated pod systems produce up to 500 liters of sterile solutions on-demand, reducing lead times, facility requirements, and quality control burdens in biomanufacturing operations.
-
![Corning HYPERStack Cell Culture]( "Cell Culture Vessels: Closed Systems For High Yield Cell Growth")
Achieve up to five times the cell growth surface area within a standard footprint. This closed system optimizes yields for stem cells and viral vectors while reducing waste and labor.
-
![Corning]( "Modular Platform For Adherent Cell Culture For Closed Systems")
Optimize adherent cell expansion with modular, closed-system platforms that provide high surface area, uniform nutrient delivery, and automated perfusion to ensure consistent cellular quality.
-
![MaxCyte - ExPERT DTx]( "ExPERT DTx™ | Electroporation For Discovery And Screening")
The ExPERT DTx™ empowers you to transfect primary cells and cell lines with minimal perturbation delivering reproducible, high transfection efficiency and cell viability.
